Capricor Therapeutics (CAPR) vs Indaptus Therapeutics (INDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Indaptus Therapeutics (INDP) has outperformed Capricor Therapeutics (CAPR) over the past year, gaining 52.4% versus a gain of 32.0%. Over five years, CAPR leads with a +122.6% price change compared with -98.3% for INDP. Capricor Therapeutics is the larger company by market cap ($441.3 million vs $433.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | INDP |
|---|---|---|
| Share price | $7.59 | $2.82 |
| Market cap | $441.30M | $433.16M |
| 1-day change | +0.80% | -9.90% |
| YTD return | -73.70% | -3.09% |
| 1-year return | +32.00% | +52.43% |
| 5-year return | +122.58% | -98.26% |
| EPS (TTM) | $-2.65 | $-3.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-105.04M | $-20.85M |
| 52-week high | $40.37 | $5.96 |
| 52-week low | $2.96 | $0.92 |
| Distance from 52-week high | -81.20% | -52.68% |
| Analyst consensus | buy | — |
| Avg. price target upside | +259.03% | — |
| Average volume | 4.73M | 712.87K |
| Shares outstanding | 58.14M | 153.60M |
| Employees | 231 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INDP has outperformed CAPR by 20.4 percentage points over the past year.
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CAPR vs INDP FAQ
Which is bigger, Capricor Therapeutics or Indaptus Therapeutics?
Capricor Therapeutics (CAPR) is larger, with a market capitalization of $441.30M compared with $433.16M for Indaptus Therapeutics (INDP).
Which stock has performed better over the past year, CAPR or INDP?
INDP returned +52.43% over the past 12 months, compared with +32.00% for CAPR (price return, excluding dividends). Past performance does not predict future results.
Are Capricor Therapeutics and Indaptus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.